share_log

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q:季报延迟披露公告
美股SEC公告 ·  08/14 07:14
Moomoo AI 已提取核心信息
bluebird bio, Inc. has filed a notification of late filing with the Securities and Exchange Commission (SEC), indicating that it will not be able to submit its Quarterly Report on Form 10-Q for the period ended June 30, 2024, by the prescribed due date of August 14, 2024. The delay is attributed to the company's ongoing efforts to restate its financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. This restatement process has also affected the timely filing of its Annual Report for 2023 and the First Quarter Report for 2024. bluebird bio is working diligently to complete the restatement and file all outstanding reports as soon as possible. The company anticipates significant changes in its results of operations for the quarter ended June 30, 2024, compared to the same period in 2023, due to identified errors in lease and non-lease component accounting in agreements with contract manufacturing organizations. However, the company has stated that these errors are not expected to impact its cash position or revenue.
bluebird bio, Inc. has filed a notification of late filing with the Securities and Exchange Commission (SEC), indicating that it will not be able to submit its Quarterly Report on Form 10-Q for the period ended June 30, 2024, by the prescribed due date of August 14, 2024. The delay is attributed to the company's ongoing efforts to restate its financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. This restatement process has also affected the timely filing of its Annual Report for 2023 and the First Quarter Report for 2024. bluebird bio is working diligently to complete the restatement and file all outstanding reports as soon as possible. The company anticipates significant changes in its results of operations for the quarter ended June 30, 2024, compared to the same period in 2023, due to identified errors in lease and non-lease component accounting in agreements with contract manufacturing organizations. However, the company has stated that these errors are not expected to impact its cash position or revenue.
bluebird bio公司向美国证券交易委员会(SEC)提交了延迟备案通知,表明其将无法在2024年8月14日的规定期限内提交截至2024年6月30日的第10-Q表格的季度报告。延误是由于公司正在努力重述截至2022年12月31日、2022年和2023年前三个季度的财务报表。这个重述过程还影响了公司2023年度报告和2024年第一季度报告的及时备案。bluebird bio正在努力完成重述,并尽快备案所有未备案报告。该公司预计,由于与合同制造组织协议中租赁和非租赁组件会计方面的已确认差错,其截至2024年6月30日的运营结果与2023年同期相比将发生重大变化。然而,该公司已表示这些差错不会影响其现金头寸或营业收入。
bluebird bio公司向美国证券交易委员会(SEC)提交了延迟备案通知,表明其将无法在2024年8月14日的规定期限内提交截至2024年6月30日的第10-Q表格的季度报告。延误是由于公司正在努力重述截至2022年12月31日、2022年和2023年前三个季度的财务报表。这个重述过程还影响了公司2023年度报告和2024年第一季度报告的及时备案。bluebird bio正在努力完成重述,并尽快备案所有未备案报告。该公司预计,由于与合同制造组织协议中租赁和非租赁组件会计方面的已确认差错,其截至2024年6月30日的运营结果与2023年同期相比将发生重大变化。然而,该公司已表示这些差错不会影响其现金头寸或营业收入。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息